A Phase III Study to Evaluate the Efficacy and Safety of of DR10624 in Subjects With Severe Hypertriglyceridemia
A Phase III Study to Evaluate the Efficacy and Safety of of DR10624 in Subjects With Severe Hypertriglyceridemia
Not yet recruiting · NCT07693777 · Registry updated 2026-07-10Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Phase III Study to Evaluate the Efficacy and Safety of of DR10624 in Subjects With Severe Hypertriglyceridemia | Digestive System Diseases, Dyslipidemias, Lipid Metabolism Disorders, Nutritional and Metabolic Diseases, fatty liver disease, hyperlipidemia, hypertriglyceridemia, liver disorder, metabolic disease, metabolic dysfunction-associated steatotic liver disease, pancreas disorder, pancreatitis | Not yet recruiting | Phase 3 | 2026-07-10 | NCT07693777 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Zhejiang Doer Biologics Co., Ltd. | 7 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Zhongshan Hospital | Shanghai | China | 10 |